Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-10

Study Completion Date

2020-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical evidence has suggested that sub-antimicrobial doses of doxycycline may have the potential to treat inflammatory lesions of acne. The efficacy of doses below 100 mg/day of doxycycline in the prevention of skin toxicity in patients with treated with Epidermal Growth Factor Receptor (EGFR)-targeted therapies has never been studied. Therefore, the aim of the present study is to describe the efficacy of doxycycline 50 or 100 mg per day in the prevention of skin toxicity in patients with metastatic Colorectal cancer (mCRC) treated with anti-EGFR in combination with chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment

NCT01380262

Colorectal Cancer Skin Toxicities

UNKNOWN

Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer

NCT01317433

Colorectal Cancer Metastatic Skin Toxicity

TERMINATED NA

Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream

NCT01345526

Metastatic Colorectal Cancer

COMPLETED PHASE2

Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response

NCT01292356

Metastatic Colon Cancer

COMPLETED PHASE2

Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors

NCT00910676

Metastatic Colorectal Cancer Non-Small-Cell Lung Carcinoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Doxycycline

Doxycycline 50 mg p.o. daily during 6 weeks

Group Type EXPERIMENTAL

Doxycycline 50Mg Tablet

Intervention Type DRUG

Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doxycycline 50Mg Tablet

Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman at least 18 years old
* Capable of understanding, signing and dating an informed consent approved by an Independent Ethics Committee (IEC)
* Histologically confirmed adenocarcinoma of the colon or rectum in patients with initially unresectable metastatic (M1) disease
* Wild-type RAS tumour status confirmed before study inclusion at local institution
* Patients who have a treatment plan based on FOLFOX + anti-EGFR or FOLFIRI + anti-EGFR, as first-line treatment of mCRC
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2
* Adequate bone marrow function: neutrophils ≥1.5 x109/L; platelets ≥100 x109/L; haemoglobin ≥9 g/dL
* Hepatic, renal and metabolic function as follows: Total bilirubin count ≤1.5 x upper limit of normal (ULN), Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) \<5 x ULN; Renal function, calculated as creatinine clearance or 24-hour creatinine clearance ≥50 mL/min; Magnesium \> lower limit of normal (LLN)

Exclusion Criteria

* History of prior or concurrent central nervous system (CNS) metastases
* History of another primary cancer, except: curatively treated in situ cervical cancer, or curatively resected non-melanoma skin cancer, or other primary solid tumour curatively treated with no known active disease present and no treatment administered for ≥5 years before treatment initiation
* Known hypersensitivity to tetracyclines
* Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma
* Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before metastatic disease was diagnosed
* Unresolved toxicities of a previous systemic treatment that, in the opinion of the investigator, cause the patient unfit for inclusion
* Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab), antivascular endothelial growth factor (VEGF) or treatment with small molecule EGFR inhibitors (e.g., erlotinib)
* Prior hormonal therapy, immunotherapy or approved or experimental antibody/proteins ≤30 days before inclusion.
* Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia
* History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computed tomography (CT)
* Treatment for systemic infection within 14 days before the start of study treatment
* Acute or subacute intestinal occlusion and/or active inflammatory bowel disease or other bowel disease that causes chronic diarrhoea (defined as grade ≥ 2 diarrhoea according to Common Terminology Criteria for Adverse Events (CTCAE)
* Clinically significant peripheral sensory neuropathy
* Evidence of previous acute hypersensitivity reaction, of any grade, to any component of the treatment
* History of Gilbert disease or known dihydropyrimidine deficiency syndrome
* Recent gastroduodenal ulcer to be active or uncontrolled
* Recent pulmonary embolism, deep vein thrombosis, or other significant venous event
* Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled anticoagulation therapy
* Recent major surgical procedure, open biopsy, or significant traumatic injury not yet recovered from prior major surgery
* History of any disease that may increase the risks associated with study participation or may interfere with the interpretation of study results.
* Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
* Any disorder that compromises the patient's ability to provide written informed consent and/or comply with study procedures
* Any investigational agent within 30 days prior to inclusion
* Pregnant or breastfeeding woman
* Surgery (excluding diagnostic biopsy or placement of a central venous catheter) and/or radiotherapy within 28 days prior to inclusion in the study.
* Male or female of childbearing age who do not agree with taking adequate contraceptive precautions, i.e. use contraception double barrier (e.g. diaphragm plus condoms) or abstinence during the course of the study and for 6 months after the last administration of study drug for women and 1 month for men
* The patient is unwilling or unable to meet the requirements of the study. Psychological, geographical, familial or sociological conditions that potentially prevent compliance with the study protocol and follow-up schedule. These conditions should be discussed with the patient before inclusion in the trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No